- In June 2025, Insight Molecular Diagnostics (iMDx) announced a landmark study comparing its digital PCR–based GraftAssureIQ assay against an NGS-based commercial test in 96 kidney transplant patients. The study, conducted at University Hospital Heidelberg, found the results were clinically equivalent, while digital PCR showed higher sensitivity in detecting low levels of donor‑derived cell‑free DNA (dd‑cfDNA)
- In January 2024, Laboratory Corporation of America Holdings launched a new test for preeclampsia in pregnant women which represents a significant advancement in maternal healthcare. This advanced diagnostic tools, healthcare providers can identify women at higher risk of severe preeclampsia earlier in their pregnancies. This allows the company for more vigilant monitoring and proactive medical intervention, potentially reducing the risk of complications and improving maternal and fetal outcomes
- In September 2023, Sonic Healthcare's acquired Healius Ltd., to provide development in the Australian healthcare landscape. This acquisition further solidifies Sonic's position as a global leader in pathology, strengthening its competitive edge against other international players. It signifies the company's commitment to expansion and consolidation within the industry, potentially paving the way for similar mergers in other regions
- In October 2023, Sonic Healthcare's invested in PaigeAI, an AI-powered pathology company, underscores their commitment to harnessing cutting-edge technology for improved diagnostic accuracy and efficiency in the field of pathology. This move holds significant implications for the future of medical diagnostics. This precision approach can lead to more effective treatments and potentially reduce the risk of side effects from unnecessary medications
